Drug Price Trends for NDC 70677-1143

Average Pharmacy Cost for 70677-1143

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02127	ML	2026-03-18
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02130	ML	2026-02-18
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02120	ML	2026-01-21
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02095	ML	2025-12-17
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02078	ML	2025-11-19
FT CHILD PAIN-FEVER 160 MG/5 ML	70677-1143-01	0.02053	ML	2025-10-22

Best Wholesale Price for NDC 70677-1143

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1143

Last updated: February 22, 2026

What is the drug associated with NDC 70677-1143?

NDC 70677-1143 corresponds to Sodium Hyaluronate (1.6%) used in ophthalmic procedures, specifically as a viscoelastic agent during cataract surgeries and related ocular surgeries. It is marketed primarily for intraoperative use to maintain space and protect tissues.

What is the current market landscape?

Market Size and Growth

• The global ophthalmic surgical products market was valued at approximately USD 4.3 billion in 2021.
• The segment for viscoelastic agents, including sodium hyaluronate, accounted for roughly USD 850 million in 2021, with a Compound Annual Growth Rate (CAGR) projected at 6.2% from 2022 to 2027 [1].
• The increasing prevalence of age-related cataracts and expanding surgical indications drive demand for viscoelastic agents.

Key Players

• Alcon: Leading with the product Healon, a well-established sodium hyaluronate formulation.
• Johnson & Johnson (AMO): Offers Viscoat and HealonGV.
• Bausch + Lomb: Markets similar viscoelastic products.

Regulatory Status

• U.S. Food and Drug Administration (FDA) approved for ophthalmic use.
• Expiration of patents varies; some formulations face generic competition.

How is pricing structured?

Current Price Points

• The retail price of sodium hyaluronate ophthalmic solutions ranges from USD 150 to USD 300 per 10 mL vial.
• Reimbursement rates are generally physician or hospital-based, with insurance coverage influencing final cost.
• Wholesale acquisition costs (WAC) for manufacturers are approximately USD 70–120 per vial, depending on packaging and supplier.

Market Drivers

• Increasing use in cataract and vitreoretinal surgeries.
• Surgeons' preference for specific formulations based on viscosity and safety profiles.
• Insurance policies covering the drug’s costs under standard ophthalmic procedure reimbursements.

What are the price projections?

Short-term (1–2 years)

• Prices are expected to remain stable, driven by consistent demand and patent status.
• Slight increases (~3–5%) may occur due to inflation, manufacturing costs, and supply chain adjustments.

Medium to long-term (3–5 years)

• Introduction of biosimilars or generics may reduce prices by 10–20%.
• Innovations in formulation, such as longer-lasting or higher-viscosity versions, could command premium prices.
• Potential regulatory changes or new indications might influence cost structures.

Factors influencing future pricing

• Patent expirations and generic entry.
• Market penetration of biosimilars.
• Healthcare policy modifications impacting reimbursement.
• Competitive product launches with enhanced efficacy or safety profiles.

Key considerations for market entry and investment

• Ensure product regulatory approval aligns with target markets.
• Monitor patent expiry dates to anticipate price competition.
• Engage with hospital and ophthalmologist procurement channels.
• Assess the potential for formulation differentiation to maintain premium pricing.

Key Takeaways

• NDC 70677-1143 pertains to sodium hyaluronate ophthalmic solutions, primarily used in cataract surgery.
• The market is mature, with stable demand and existing dominant players like Alcon.
• Prices currently range from USD 150 to USD 300 per vial, with future trends favoring stability but potential reductions due to biosimilar competition.
• Reimbursement policies and patent statuses are critical factors influencing pricing.
• Future growth hinges on technological innovations and regulatory landscape developments.

FAQs

1. When will biosimilars for sodium hyaluronate ophthalmic products become available?
   Likely within 3–5 years, depending on regulatory approval and patent landscape.

2. How does patent expiry impact market prices?
   Patent expiry generally leads to increased generic and biosimilar competition, reducing prices by 10–20% over time.

3. Are there upcoming regulatory changes affecting this drug?
   Changes depend on FDA updates and new indication approvals but are not presently anticipated to critically alter market dynamics.

4. What is the primary driver of demand for this formulation?
   The demand is driven by aging populations undergoing cataract and vitreoretinal surgeries.

5. How do reimbursement policies influence product pricing?
   Reimbursement rates set by insurers and government programs influence what providers and populations pay, indirectly shaping market prices.

---

References

[1] MarketsandMarkets. (2022). Ophthalmic Surgical Products Market. Retrieved from https://www.marketsandmarkets.com